Imperial College London, Isle of Wight NHS Trust, Newport, UK.
Imperial College Healthcare NHS Trust, London, UK.
Eur J Haematol. 2024 Apr;112(4):611-620. doi: 10.1111/ejh.14152. Epub 2023 Dec 19.
Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato-Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression-free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation-Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non-inferiority. The HOF score is a new score with the potential for application in different haematological malignancies.
老年人血液恶性肿瘤患者在化疗期间的发病率和死亡率可能难以预测。先前发现血液肿瘤衰弱（HOF）评分可预测浆细胞瘤患者队列的结局。在这项研究中，我们评估了其在评估淋巴瘤患者衰弱程度方面的效用，并将其与另外两种衰弱评分进行了比较。HOF 评分能够预测该人群的无进展生存期，并且还显示出在化疗期间评估衰弱动态的潜力。与 Charlson 合并症指数（CCI）评分和造血细胞移植特异性合并症指数（HCTCI）相比，它的表现也很好，尽管该研究没有能力评估非劣效性。HOF 评分是一种新的评分，具有在不同血液恶性肿瘤中应用的潜力。
